Using susceptibility-weighted imaging to determine response to combined antiangiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme

Neuro-Oncology

Volumn 15, Issue 4, 2013, Pages 480-489

  Lupo, Janine M ^a   Essock Burns, Emma ^a   Molinaro, Annette M ^a   Cha, Soonmee ^a   Chang, Susan M ^a   Butowski, Nicholas ^a   Nelson, Sarah J ^a,b  

^a Department of Radiology and Biomedical Imaging ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioma; Response to anti angiogenic therapy; Susceptibility weighted imaging

Indexed keywords

ENZASTAURIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; SUSCEPTIBILITY WEIGHTED IMAGING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDOLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84875691055     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos325     Document Type: Article

References (45)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65-71.
2. Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A. Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review. Eur Rev Med Pharmacol Sci. 1997;1(1-3):17-25.
3. Brat DJ, Van Meir EG. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol. 2001;158(3):789-796.
4. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 1997;57(17): 3860-3864.
5. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol. 1997;32(3):253-265.
6. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
7. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
8. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
9. Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 2011;50(5):630-635.
10. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29(2):142-148.
11. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12(12):1300-1310.
12. Hasselbalch B, Eriksen JG, Broholm H, et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS. 2010;118(8):585-594.
13. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of singleagent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297-5305.
14. Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery. 2010;67(1):87-93.
15. Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci. 2010;17(8):970-974.
16. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12(5):508-516.
17. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76(5):432-437.
18. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010;12(6):608-613.
19. Kreisl TN, Kotliarova S, Butman JA, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010; 12(2):181-189.
20. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol. 2002;49:69-77.
21. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008;17:939-944.
22. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61:153-161.
23. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741-1746.
24. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168-1174.
25. Butowski N, Chang SM, Lamborn KR, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011;13(12):1331-1338.
26. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11: 83-95.
27. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92(2):149-155.
28. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28(17):2817-2823.
29. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12(8):855-861.
30. Hainsworth JD, Ervin T, Friedman E, et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010; 116(15):3663-3669.
31. Neyns B, Sadones J, Chaskis C, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2011;103(3): 491-501.
32. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34): 5610-5617.
33. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16):2712-2718.
34. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-989.
35. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67:2729-2735.
36. Essock-Burns E, Lupo JM, Cha S, et al. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13(1):119-131.
37. Lupo JM, Lee MC, Cha S, Chang SM, Nelson SJ. Imaging blood vessel volume in high grade gliomas at 3T using susceptibility-weighted imaging and dynamic susceptibility contrast perfusion MRI [abstract]. Proceedings of the 14th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 8-12 May, 2006.
38. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibilityweighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30(7):1402-1408.
39. Lupo JM, Chang SM, Nelson SJ. Using 7T susceptibility-weighted imaging to aid in the characterization of high-grade gliomas [abstract]. Proceedings of the 16th Annual Meeting of the International Society for Magnetic Resonance in Medicine; 3-9 May, 2008.
40. Lupo JM, Banerjee S, Hammond KE, et al. GRAPPA-based susceptibility- weighted imaging of normal volunteers and patients with brain tumor at 7 T. Magn Reson Imaging. 2009;27(4):480-488.
41. Studholme C, Hill D, Hawkes D. An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognit. 1999; 32:71-86.
42. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
43. Therneau TM, Atkinson EJ. An in-troduction to recursive partitioning using the RPART routines. Technical Report. Mayo Foundation, 1997.
44. Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5:634-644.
45. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27: 2905-2908.